文献类型：期刊文献

英文题名：Er Shen Wan extract alleviates polyuria and regulates AQP 2 and AVPR 2 in a rat model of spleen-kidney Yang deficiency-induced diarrhea

作者：Xiong, Rui[1,2];Li, Yidan[1];Zheng, Kaixuan[1];Zhang, Tingting[1];Gao, Mingyang[1];Li, Yun[1,4];Lian, Yumei[1];Chen, Da[1];Hu, Changjiang[3]

第一作者：Xiong, Rui

通信作者：Hu, CJ[1]

机构：[1]Chengdu Univ Tradit Chinese Med, Coll Pharm, Chengdu 610075, Sichuan, Peoples R China;[2]Guiyang Coll Tradit Chinese Med, Coll Pharm, Guiyang 550002, Guizhou, Peoples R China;[3]Sichuan Neogreen Pharmaceut Technol Dev Co Ltd, Chengdu 610081, Sichuan, Peoples R China;[4]Gansu Univ Tradit Chinese Med, Coll Pharm, Lanzhou 730000, Gansu, Peoples R China

第一机构：Chengdu Univ Tradit Chinese Med, Coll Pharm, Chengdu 610075, Sichuan, Peoples R China

通信机构：[1]corresponding author), Chengdu Univ Tradit Chinese Med, Coll Pharm, Chengdu 610081, Sichuan, Peoples R China.

年份：2019

卷号：110

起止页码：302

外文期刊名：BIOMEDICINE & PHARMACOTHERAPY

收录：;Scopus(收录号：2-s2.0-85057524309);WOS:【SCI-EXPANDED(收录号:WOS:000454879800033)】；

基金：This work was funded by grants from the Fund for Fostering Talents in Basic Science of the National Natural Science Foundation of China (J13100340) and the General Program of the National Natural Science Foundation of China (81274085), College of Pharmacy, Chengdu University of Traditional Chinese Medicine.

语种：英文

外文关键词：Er Shen Wan; Extract; Polyuria; AQP 2; AVPR 2

摘要：Ethnopharmacological relevance: Er Shen Wan (ESW), has been empirically used for treating spleen-kidney Yang deficiency (SKYD) syndrome in Traditional Chinese medicine (TCM) for centuries and shows a variety of activities. The medicinal formula is a mixture of two component herbs, Psoraleae Fructus (PF, Bu-Gu-Zhi in Chinese) and Myristicae Semen (MS, Rou-Dou-Kou in Chinese). The current study was designed to evaluate ESWP antidiuretic treatment of polyuria and to explore potential mechanisms of renal water metabolism in the rat model of SKYD-induced diarrhea. Materials and methods: An animal model of 'SKYD-induced diarrhea syndrome' has been established to evaluate the therapeutic effect and action mechanism according to the clinical syndrome and symptoms. The optimal dose (3.5 g/kg) of ESWP was given to rats by gavage for two weeks. Urinary volumes after 24 h were recorded. After the end of the trial, macroscopic morphological and histological examination of the kidney were conducted. Serum levels of Arginine vasopressin (AVP) and aldosterone (ALD) were also measured. Additionally, quantitative real-time RT-PCR (RT-qPCR) and immunohistochemistry (IHC) analyses were performed to clarify the regulation of aquaporin 2 (AQP 2) and arginine vasopressin type 2 receptor (AVPR 2) in the kidney at the gene and tissue expression levels respectively. Results: After the administration of ESWP, urinary output volume after 24 h was found to be significantly decreased in rats. Elevated plasma levels of AVP and ALD were detected. Histological kidney damage appeared to be impeded, and histological disease scores were reduced. In addition, the expression levels of AQP 2 and AVPR 2 were significantly increased. Conclusion: This study suggests that ESWP may elicit significant effects on the treatment of polyuria. Potential mechanisms at least partially involve hormone regulation, and alleviating renal pathological damage. Simultaneously, ESWP may alter renal water absorption by increasing AQP 2 and AVPR 2 expression levels. Thus, the in vivo experimental evidence indicates that ESWP has a therapeutic effect on the SKYD syndrome, which is consistent with its traditional usage.